Clinical Edit Criteria Proposal

Drug/Drug Class: Dolgic LQ® (Acetaminophen/Butalbital/Caffeine) Clinical Edit

Prepared for: Missouri Medicaid
Prepared by: Heritage Information Systems, Inc.

☐ New Criteria  ■ Revision of Existing Criteria

Executive Summary

Purpose: Encourage the use of generic oral tablet and capsule forms.

Why was this Issue Selected: Dolgic LQ® is a combination liquid product containing acetaminophen, butalbital, and caffeine. It provides a liquid alternative for patients who cannot swallow generic acetaminophen/butalbital/caffeine tablet and capsule combination products.

Drug Program-specific information: Acetaminophen 325mg / butalbital 50mg / caffeine 40mg tablets
Dolgic LQ® $0.6542/5ml

AWP

Setting & Population: NA

Type of Criteria: □ Increased risk of ADE  ☒ Appropriate Indications  □ Non-Preferred Agent

Data Sources: ☒ Only administrative databases  □ Databases + Prescriber-supplied
<table>
<thead>
<tr>
<th>Purpose of Clinical Edit Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Under the Omnibus Budget Reconciliation Act of 1993, Congress intended Prior Authorization or Prior Approval (PA) programs to control utilization of products that have very narrow indications or high abuse potential. While prescription expenditures are increasing at double-digit rates, payors are also evaluating ways to control these costs by influencing prescriber behavior and guide appropriate medication usage. Clinical Edit criteria, which is different from prior authorization or prior approval programs, assist in the achievement of qualitative and economic goals related to health care resource utilization without placing the entire utilization of a drug in a PA status. Screening the use of certain medications on the basis of clinical appropriateness can reduce costs by requiring evidence of appropriate indications for use, and where appropriate, encourage the use of less expensive agents within a drug class. Clinical Edit criteria can also reduce the risk for adverse events associated with medications by identifying patients at increased risk due to diseases or medical conditions, or those in need of dosing modifications.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Setting &amp; Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Drug class for review: Dolgic LQ®</td>
</tr>
<tr>
<td>• Age range: All patients</td>
</tr>
<tr>
<td>• Diagnosis: NA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Approval Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Diagnosis of Migraines (ICD-9=346; includes vasomotor headaches) and tension headaches (ICD-9=307.81).</td>
</tr>
<tr>
<td>• Prescription claim history of generic acetaminophen,butalbital/caffeine combination tablets or capsules.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Denial Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Lack of diagnostic evidence pertaining to migraine and tension headaches.</td>
</tr>
<tr>
<td>• Lack of evidence of trial and failure on generic acetaminophen,butalbital/caffeine combination tablets and capsules.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Required Documentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory results:</td>
</tr>
<tr>
<td>MedWatch form:</td>
</tr>
<tr>
<td>Progress notes:</td>
</tr>
<tr>
<td>Other:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disposition of Edit</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Denial: Edit 682 “Clinical Edit”</td>
</tr>
</tbody>
</table>
References